09 September 2022 | News
The tablet will be sold under the brand name Paxzen
Image credit: www.yalemedicine.org
Hyderabad-based Zenara Pharma, a fully-owned subsidiary of Biophore India Pharmaceuticals, has launched Nirmatrelvir and Ritonavir tablets in a combi pack as a treatment option for patients with mild to moderate symptoms of COVID-19.
It is to be noted that Zenara Pharma received approval from the Central Drugs Standard Control Organization (CDSCO) to manufacture and market this product last month.
The tablet, which will be sold under the brand name ‘Paxzen’, is being manufactured at Zenara’s US FDA and EU-approved state-of-the-art facility in Hyderabad.
The product will be sold at a maximum retail price of Rs 5,200 per box, equivalent to one full course of treatment per patient, and contains 20 Tablets of Nirmatrelvir 150 ml and 10 tablets of Ritonavir 100 mg.